EDITOR'S PICKS

More>>
LATEST MOST VIEWED: LAST ONE YEAR MOST VIEWED: LAST TWO YEARS MOST DOWNLOADED
  • image
    Original Article| Open Access

    Neoadjuvant hepatic arterial infusion chemotherapy for resectable hepatocellular carcinomas

    Rina Tsutsui , Hiroaki Nagamatsu , Osamu Itano , Akihiro Deguchi , Tsubasa Tsutsumi , Mamoru Hiraki , Naohisa Mizukami , Jun Akiba

    Aim: To evaluate the effect of neoadjuvant hepatic arterial infusion chemotherapy (HAIC) on the survival of patients with resectable hepatocellular carcinoma (HCC). Methods: Between January 2003 and January 2014, 80 patients underwent hepatic resection for HCC. Of these patients, we evaluated 49... Read more

    Hepatoma Res 2018;4:13. | doi:10.20517/2394-5079.2018.20
    Published on: 11 May 2018  | Viewed:638  | Downloaded:26
    +HTML| PDF
  • image
    Original Article| Open Access

    Beta2-glycoprotein I cooperate with hepatitis B surface antigen promotes hepatocellular carcinogenesis via the nuclear factor kappa B signal pathway were enhanced by the lipopolysaccharide

    Xue-Li Ding , Xue Jing , Nai-Jun Han , Zi-Bin Tian , Pu-Jun Gao , Lin Yang , Ya-Nan Yu

    Aim: We aimed to elucidate whether beta2-glycoprotein I (β2GPI) cooperation with hepatitis B surface antigen (HBsAg) promoted hepatocellular carcinogenesis enhanced by the lipopolysaccharide (LPS) via activation of nuclear factor kappa B (NF-κB) and expression of tumor necrosis factor-α (TNF-α),... Read more

    This article belongs to the Special Issue Molecular Mechanism of Hepatocellular Carcinoma Hepatoma Res 2018;4:12. | doi:10.20517/2394-5079.2018.07
    Published on: 28 Apr 2018  | Viewed:345  | Downloaded:21
    +HTML| PDF
  • image
    Review| Open Access

    Systemic therapies for hepatocellular carcinoma: a recap of the current status

    Petros Giovanis , Manuela De Bona , Fabio Farinati , Andrea Buda , Riccardo Berletti , Fable Zustovich , Simona D’Ippolito , Michele De Boni , Umberto Cillo , Davide Pastorelli

    After decades of frustrating nihilism due to lack of innovative therapeutic solutions, the onco-hepatological community is facing up to important novelties for the treatment of intermediate and advanced stages of liver cancer. Four new drugs have been investigated and resulted in positive data:... Read more

    This article belongs to the Special Issue Management of Hepatocellular Carcinoma Hepatoma Res 2018;4:10. | doi:10.20517/2394-5079.2018.21
    Published on: 27 Apr 2018  | Viewed:735  | Downloaded:68
    +HTML| PDF
  • image
    Original Article| Open Access

    A potential clinical based score in hepatitis C virus cirrhotic patients to exclude small hepatocellular carcinoma

    Denise Cerqueira Paranaguá-Vezozzo , Celso Eduardo Lourenço Matielo , Daniel Ferraz de Campos Mazo , Lucas Souto Nacif , Mario Guimaraes Pessoa , Gleicy Luz Reinoso Pereira , Roque Gabriel Rezende de Lima , Patricia Momoyo Yoshimura Zitelli , Suzane Kioko Ono , Flair José Carrilho

    Aim: Hepatitis C virus (HCV) cirrhosis is an important cause of hepatocellular carcinoma (HCC). This study aimed to identify factors of HCC presence among HCV cirrhotic patients with and without small diameter HCC (≤ 3 cm). Methods: A case control transversal study between 1998 and 2003 including... Read more

    This article belongs to the Special Issue Management of Hepatocellular Carcinoma Hepatoma Res 2018;4:11. | doi:10.20517/2394-5079.2018.17
    Published on: 27 Apr 2018  | Viewed:619  | Downloaded:42
    +HTML| PDF
  • image
    Original Article| Open Access

    Lycopene treatment stalls the onset of experimentally induced hepatocellular carcinoma: a radioisotopic, physiological and biochemical analysis

    Nisha Bhatia , Baljinder Singh , Ashwani Koul

    Aim: The present study was aimed to determine the modulatory role of lycopene enriched tomato extract (LycT) during initiation of N-nitrosodiethylamine (NDEA) induced hepatocellular carcinoma (HCC). Methods: Female Balb/c mice were divided into 4 groups: control, NDEA (200 mg NDEA/kg b.wt,... Read more

    This article belongs to the Special Issue Molecular Mechanism of Hepatocellular Carcinoma Hepatoma Res 2018;4:9. | doi:10.20517/2394-5079.2018.04
    Published on: 27 Mar 2018  | Viewed:654  | Downloaded:18
    +HTML| PDF
  • image
    Original Article| Open Access

    Prediction of post-progression survival in patients with advanced hepatocellular carcinoma treated with sorafenib by using time-dependent changes in clinical characteristics

    Yoshiyuki Wada , Yuko Takami , Hajime Matsushima , Masaki Tateishi , Tomoki Ryu , Munehiro Yoshitomi , Hideki Saitsu

    Aim: Sorafenib has been shown to improve time to tumor progression (TTP) and overall survival (OS) in patients with hepatocellular carcinoma (HCC); however, post-progression survival (PPS) has not been well characterized in these patients. This study aimed to evaluate the predictors of PPS by... Read more

    Hepatoma Res 2018;4:8. | doi:10.20517/2394-5079.2017.39
    Published on: 6 Mar 2018  | Viewed:1159  | Downloaded:85
    +HTML| PDF
  • image
    Case Report| Open Access

    Congenital absence of the portal vein complicated by hepatocellular carcinoma in the liver of an adult woman: review of imaging, literature and management

    Ankit Mehta , Shree R. Venkat , Lorraine Portelance , Lynn G. Feun

    We present a case of absence of the portal vein and Laennec’s cirrhosis in a 51-year-old female who was diagnosed with hepatocellular carcinoma (HCC). Only 101 cases of this malformation of the splanchnic vasculature have been reported of which 4 were reported to have HCC. Patient had disease... Read more

    This article belongs to the Special Issue Novel Approaches for HCC Hepatoma Res 2018;4:7. | doi:10.20517/2394-5079.2017.35
    Published on: 27 Feb 2018  | Viewed:1444  | Downloaded:61
    +HTML| PDF
  • image
    Review| Open Access

    Direct antiviral therapy for hepatitis C and hepatocellular carcinoma: facing the conundrum

    Federica Buonfiglioli , Stefano Brillanti

    Direct antiviral therapy has dramatically changed our possibility to eradicate hepatitis C virus (HCV) infection in all stages of chronic liver disease, with sustained virological response rates well above 90%. HCV eradication should lead to a better prognosis even after cirrhosis has... Read more

    Hepatoma Res 2018;4:6. | doi:10.20517/2394-5079.2017.42
    Published on: 10 Feb 2018  | Viewed:2084  | Downloaded:158
    +HTML| PDF
  • image
    Review| Open Access

    Treatment of high-burden hepatocellular carcinoma: an oncologist perspective

    Landon L. Chan , Stephen L. Chan

    Hepatocellular carcinoma (HCC) is recognized as a major global healthcare burden. Although there have been tremendous improvements in cancer screening and treatment, HCC mortality rate remains high. Many patients with HCC present late to medical attention and thus are not candidates for curative... Read more

    This article belongs to the Special Issue Management of Huge and Advanced Hepatocellular Carcinoma Hepatoma Res 2018;4:5. | doi:10.20517/2394-5079.2017.49
    Published on: 7 Feb 2018  | Viewed:1846  | Downloaded:100
    +HTML| PDF
  • image
    Cohort Profile| Open Access

    Qidong hepatitis B virus infection cohort: a 25-year prospective study in high risk area of primary liver cancer

    Tao-Yang Chen , Geng-Sun Qian , Chun-Sun Fan , Yan Sun , Jin-Bing Wang , Pei-Xin Lu , Xue-Feng Xue , Yan Wu , Qi-Nan Zhang , Yan Jin , Yi-Qian Wu , Yu Gan , Jian-Quan Lu , Thomas W. Kensler , John D. Groopman , Hong Tu

    Qidong hepatitis B virus (HBV) infection cohort (QBC) is a prospective community-based study designed to investigate causative factors of primary liver cancer (PLC) in Qidong, China, where both PLC and HBV infection are highly endemic. Residents aged 20-65 years, living in seven townships of... Read more

    Hepatoma Res 2018;4:4. | doi:10.20517/2394-5079.2017.50
    Published on: 26 Jan 2018  | Viewed:2043  | Downloaded:84
    +HTML| PDF
+MoreView all articles
Subscribe

To receive email updates about the journal, please subscribe here.

News More>>
Partners
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.